Key result
POSTBIO-HF evaluates the prognostic value of short-term biomarker follow-up in ADHF.
Why the study?
Data on the prognostic value of surrogate biomarkers during short-term follow-up after discharge in acute decompensated HF are scarce.
Does short-term follow-up of multiple biomarkers (NT-proBNP, GDF-15, troponin-T, hs-CRP, urinary ACR) improve risk prediction for cardiovascular mortality or HF hospitalization in hospitalized patients with acute decompensated HF?
Observational (n=1,500)
Yes
Does short-term follow-up of multiple biomarkers (NT-proBNP, GDF-15, troponin-T, hs-CRP, urinary ACR) improve risk prediction for cardiovascular mortality or HF hospitalization in hospitalized patients with acute decompensated HF?
The POSTBIO-HF prospective observational study is designed to evaluate whether serial measurements of multiple biomarkers after discharge can improve risk stratification in patients with acute decompensated heart failure.
Serial biomarker monitoring in acute decompensated HF is hypothesis-generating; leaves open incremental value for mortality or hospitalization risk prediction.
Several surrogate biomarkers possess prognostic significance for heart failure (HF), and a decline in their respective values may predict clinical improvement. However, data on the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated HF are scarce. We aim to evaluate the prognostic value of short-term follow-up of surrogate biomarkers for predicting the prognosis of hospitalized patients with acute decompensated HF. This multi-center, prospective study will enroll consecutive hospitalized patients with acute decompensated HF. All patients will undergo sampling and comparison of biomarkers, including plasma N-terminal pro-brain natriuretic peptide, growth differentiation factor 15, troponin-T, high-sensitivity C-reactive protein, and urinary albumin/creatinine ratio obtained within 1 month and 6 months after discharge from the index admission. The primary endpoint is a composite of cardiovascular mortality or HF hospitalization during 1 year of follow-up. We will investigate the prognostic value of multiple biomarkers for the primary endpoint. This trial will provide robust evidence for novel multi-biomarker strategies for acute decompensated HF in real-world settings. Trial Registration: ClinicalTrials.gov Identifier: NCT04437628.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2022) conducted an observational in Acute decompensated heart failure (n=1,500). Short-term follow-up of multiple biomarkers (NT-proBNP, GDF-15, troponin-T, hs-CRP, urinary ACR) was evaluated on Composite of cardiovascular mortality or HF hospitalization. The POSTBIO-HF trial is a prospective observational study designed to evaluate the prognostic value of short-term follow-up of multiple biomarkers in 1,500 hospitalized patients with acute decompensated heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: